Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECREASE: Dapagliflozin and Exenatide in Obese T2DM
NCT03361098Phase 4Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2017
- Primary completion
- Nov 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin and exenatide in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Neuronal activity in central reward and satiety circuits at 16 weeks. Started Sep 2017; status: completed.
02
Drugs
dapagliflozinexenatide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT03361098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03361098.